echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Ferritin may become a marker for the diagnosis, differential diagnosis and prognosis of IrAEs

    Ferritin may become a marker for the diagnosis, differential diagnosis and prognosis of IrAEs

    • Last Update: 2021-08-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Immune Checkpoint Inhibitors (ICIs) can restore the proliferation and effect of T cells, snipe escaping tumor cells, and are currently hot star drugs in the field of solid tumors and hematological tumors
    .

    But it can produce immune-related adverse events (irAEs)
    .


    IrAEs can affect any tissue or organ, and if they are handled improperly, they can directly affect the survival benefit of anti-tumor drugs


    But it is very similar to AEs caused by chemotherapy, targeted therapy or infection, and it is not easy to distinguish them completely
    .


    In this regard, some scholars recently proposed that ferritin can be used as a marker for the diagnosis, differential diagnosis and prognosis of IrAEs


    Ferritin can be used as a marker for the diagnosis, differential diagnosis and prognosis of IrAEs


    On Cancer Biol Med


    Research methods

    Research methods

    The researchers included a total of 318 patients with malignant tumors, of which 231 patients were receiving PD-1 inhibitors or combined chemotherapy, and 87 patients were receiving chemotherapy only
    .

    Among the 231 patients, they can be divided into irAE group (90 people with irAE), non-irAE group (70 people without irAE), AE group (4 people with AE) and non-irAE-no AE group (67 people, Neither irAE nor AE)
    .

    Among the 87 patients, they can be divided into an AE group (60 people, with AE) and a non-AE group (27 people, without AE)
    .

    Among the 231 patients, they can be divided into irAE group (90 people with irAE), non-irAE group (70 people without irAE), AE group (4 people with AE) and non-irAE-no AE group (67 people, Neither irAE nor AE)
    .

    Among the 87 patients, they can be divided into an AE group (60 people, with AE) and a non-AE group (27 people, without AE)
    .

    Analysis conclusion

    Analysis conclusion

    Through 4 months of serum ferritin monitoring, it was found that:

    When adverse events occurred in the irAE group, the ferritin content (normal range 35-150μg/L) rose from the baseline value of 86μg/L to the median value of 927μg/L
    .

    When adverse events occurred in the irAE group, the ferritin content was significantly higher than that of the non-irAE group and the AE group
    .

    At the same time, the researchers also found that after treatment in the irAE group, the ferritin content of the patients will gradually drop to the normal range
    .

    When adverse events occurred in the irAE group, the ferritin content (normal range 35-150μg/L) rose from the baseline value of 86μg/L to the median value of 927μg/L
    .

    When adverse events occurred in the irAE group, the ferritin content (normal range 35-150μg/L) rose from the baseline value of 86μg/L to the median value of 927μg/L
    .


    When adverse events occurred in the irAE group, the ferritin content was significantly higher than that of the non-irAE group and the AE group
    .

    When adverse events occurred in the irAE group, the ferritin content was significantly higher than that of the non-irAE group and the AE group
    .


    At the same time, the researchers also found that after treatment in the irAE group, the ferritin content of the patients will gradually drop to the normal range
    .

    At the same time, the researchers also found that after treatment in the irAE group, the ferritin content of the patients will gradually drop to the normal range
    .


    It can be seen that ferritin is a marker that can determine whether a patient has irAE and prognosis
    .

     

    Literature source :

    Literature source

    Weihong Zhang, et al.


    Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.